MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

13.84 -0.29 (-2.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million ↗
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive (ADPT) Q1 2026 Earnings Transcript ↗
Adaptive (ADPT) Q1 2026 Earnings Transcript 
Via The Motley Fool
Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
Adaptive Biotechnologies (NASDAQ:ADPT) Reports Strong Q4 Revenue Beat and Path to Profitability ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. ↗
This immune diagnostics innovator reported a notable insider sale as it advances platforms for disease detection and monitoring. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means ↗
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? ↗
This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On ↗
This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look ↗
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year ↗
Adaptive Biotechnologies, a leader in immune-driven diagnostics, saw a notable insider sale amid ongoing innovation in disease monitoring. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price ↗
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale after a strong one-year stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech (ADPT) Earnings Call Transcript ↗
Adaptive Biotech (ADPT) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that... 
Via MarketMinute
News headline image
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗
Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam... 
Via Benzinga
News headline image
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 Analysts ↗
 
Via Benzinga
News headline image
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies (NASDAQ:ADPT) Fits Minervini's Trend Template with Strong Growth Momentum ↗
Adaptive Biotechnologies (ADPT) aligns with Minervini's trend and high-growth momentum strategies, showing strong technicals, rising earnings, and revenue growth. A top pick for trend investors. 
Via Chartmill
News headline image
Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday ↗
One of the company's businesses is particularly hot at the moment. 
Via The Motley Fool
News headline image
Adaptive (ADPT) Q2 Revenue Surges 36% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics ↗
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation. 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet ↗
 
Via Benzinga
News headline image
Assessing Adaptive Biotechnologies: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
ADAPTIVE BIOTECHNOLOGIES (NASDAQ:ADPT) – A High-Growth Stock Meeting Minervini’s Trend Template ↗
ADAPTIVE BIOTECHNOLOGIES (ADPT) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a compelling candidate for momentum investors. 
Via Chartmill
News headline image
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration ↗
Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds. 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story